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Abstract  1 
Background: Optic neuritis (ON) may be monophasic or occur as part of a relapsing demyelinating 2 
syndrome (RDS), such as MS, AQP4-Ab neuromyelitis optical spectrum disorder (NMOSD) or MOG-3 
Ab-associated disease.  4 
 5 
Methods: 42 children were retrospectively studied; 22 with MS (MS-ON) and 20 with Ab-associated 6 
demyelination (Ab-ON: MOG-Ab=16 and AQP4-Ab=4). Clinical and paraclinical features were analysed. 7 
 8 
Results: Complete recovery of visual acuity (VA) was reported in 25/42 (60%) children; 8/38 (21%) 9 
suffered moderate or severe visual impairment (logMAR>0.5) in their worst eye, including 4/38 (11%) 10 
who were blind (logMAR>1.3) in their worst eye (2 MS, 2 AQP4-Ab NMOSD). None of the children with 11 
MOG-Ab were blind. Recurrence of ON was more common in the Ab-ON vs MS-ON group (15/20 vs 12 
7/22, p=0.0068). RNFL thickness at baseline inversely correlated with total number of ON episodes 13 
(r=0.38, p=0.0062) and VA at final follow-up (r=-0.42, p=0.0023). There was no correlation between 14 
number of ON episodes and visual outcome.  15 
 16 
Conclusion: In children with RDS, long-term visual impairment inversely correlated with RNFL 17 
thickness, but not with number of ON relapses. OCT may have a role in the assessment of children with 18 
ON to monitor disease activity and inform treatment decisions. 19 
 20 
 21 
What this paper adds: 22 
 40% of children with relapsing demyelinating syndromes (RDS) suffer long-term visual 23 
impairment following optic neuritis (ON). 24 
 Relapse of ON, occurring more frequently in the non-MS group, is not correlated with final 25 
visual outcome. 26 
 Thinning of the retinal nerve fibre layer, as visualised by optical coherence tomography (OCT), 27 
is associated with worse visual outcome. 28 
 OCT can be used alongside clinical parameters in children with RDS as an objective measure 29 
of neuroretinal loss. 30 
 31 
 32 
  33 
 3 
Introduction  34 
Optic neuritis (ON), defined as inflammation of one or both optic nerves in association with visual 35 
dysfunction, is one of the commonest presentations of acquired CNS demyelination in childhood, with 36 
an incidence of approximately 0.2 per 100,0001. Core deficits in visual acuity (VA), colour perception 37 
and visual field are commonly accompanied by ocular pain and headache2. 60-77% of children suffer 38 
severely decreased VA (worse than logMAR 1.0 or Snellen 20/200) in the acute phase3-5.  ON may 39 
occur in isolation (idiopathic ON) or be associated with a relapsing demyelinating syndrome (RDS), 40 
such as multiple sclerosis (MS), aquaporin-4 antibody (AQP4-Ab) neuromyelitis optica spectrum 41 
disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) Ab-associated disease. Frequent 42 
involvement of the optic nerve in RDS may be due to the more permeable blood-brain barrier at the 43 
optic nerve compared to other CNS sites6.  44 
 45 
Optical coherence tomography (OCT) and electrodiagnostic tests can be useful paraclinical parameters 46 
in patients with optic neuritis7. OCT may detect structural retinal changes, such as retinal nerve fibre 47 
layer (RNFL) and ganglion cell layer thinning, and the development of microcystic macular oedema and 48 
retinal damage. OCT may help to differentiate between MS and NMOSD, with more severe retinal 49 
damage and hence greater RNFL thinning detected following optic neuritis in patients with AQP4-Ab 50 
NMOSD8. Studies carried out in adult cohorts have shown that RNFL thickness is reduced in both ON 51 
and non-ON eyes compared to healthy controls9, and predicts visual function after ON10, and disease 52 
activity11 and disability12 in MS. 53 
 54 
Electrodiagnostic tests, particularly visual evoked potentials (VEP), may reveal loss of functional 55 
integrity in the optic pathway due to demyelination. VEP is a distinct measure of visual function from 56 
high-contrast VA (HCVA) and the two can be discrepant, especially in cases of optic atrophy. VEP 57 
correlates with other measures of visual function, such as contrast sensitivity and low contrast letter 58 
acuity. VEP can also be used to identify clinically silent ON13: a recent study of 24 patients with 59 
paediatric-onset MS detected prolonged VEP latency in 58% of ON eyes, but also in 55% of non-ON 60 
eyes, highlighting that subclinical involvement of the optic nerve is common in children with MS14. The 61 
prognostic value of both OCT and VEP in predicting future ON relapse and long-term visual outcome in 62 
children with RDS is yet to be evaluated.  63 
 64 
Full recovery of HCVA occurs in the majority of children presenting with ON2, 15, but subtle deficits may 65 
persist, particularly in low contrast and colour vision2. Furthermore, in a subset of patients with AQP4-66 
Ab positive NMOSD and MOG-Ab-associated disease, frequent attacks are often associated with 67 
accumulating damage and functional impairment of vision, with severe impairment (functional 68 
blindness) in 18%16 and 36%17 of patients respectively. In adults, high-dose corticosteroid treatment 69 
hastens the recovery from acute ON18, but does not influence final visual outcome or the risk of 70 
 4 
subsequent MS19. Encouraging results from randomized-controlled trials of phenytoin20 and 71 
erythropoietin21 in ON suggest that neuroprotective agents, besides immunotherapy, may be of utility in 72 
acute demyelination and OCT may be used to provide outcome measures to test the efficacy of 73 
medications. 74 
 75 
The aims of this study were to (1) test whether clinical, electrophysiological and microstructural 76 
parameters differ in MS-ON and Ab-ON; (2) identify the clinical and paraclinical characteristics of 77 
children suffering worse long-term visual outcome of RDS-ON; and (3) explore the relationship between 78 
RNFL thickness and clinical parameters in RDS-ON. 79 
 80 
Patients and methods 81 
Participants  82 
Children presented to three UK & Ireland Childhood CNS Inflammatory Demyelination Working Group 83 
(UK-CID) centres: Great Ormond Street Hospital, Evelina London Children’s Hospital, and Birmingham 84 
Children’s Hospital. The diagnosis of RDS was defined as two or more episodes of acquired CNS 85 
demyelination lasting >24 hours, involving the optic nerve, brain or spinal cord, associated with T2 86 
lesions on MRI. In this retrospective study, we included children with history of at least one episode of 87 
ON and the following RDS diagnoses: MS, AQP4-Ab NMOSD and MOG-Ab-associated demyelination. 88 
Patients with antibody-negative RDS were excluded. A diagnosis of ON was confirmed by an 89 
experienced neuro-ophthalmologist on the basis of history of reduced HCVA, red desaturation, pain with 90 
ocular movement, and/or visual field defect. Complete visual recovery was defined by normal HCVA, 91 
normal colour vision and normal visual fields.   92 
 93 
All investigations were undertaken as part of the routine diagnostic protocols of participating centres. 94 
MR imaging of the brain and spinal cord was undertaken in all cases. Within 1 month of an acute 95 
demyelination event, clinically symptomatic children underwent testing for serum AQP4-Ab and MOG-96 
Ab (not CSF), as part of routine assessments of children with demyelinating diseases, performed at the 97 
Clinical Neuroimmunology service at the Oxford Radcliffe Hospital Trust, using live cell-based assays22, 98 
23.  99 
 100 
Assessments of visual function were carried out by ophthalmology departments at the three centres, 101 
including HCVA measured by the logarithm of the minimum angle of resolution (logMAR) and colour 102 
vision measured by Ishihara plates. Electrodiagnostic tests (EDT) methods for children have been 103 
described previously24. In brief, monocular VEPs were recorded from Oz referred to a mid-frontal 104 
electrode according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards25 105 
and were acquired and analysed using a Espion E3 system (Diagnosys LLC, Cambridge UK). Pattern 106 
reversal and onset VEPs were produced by high contrast, black and white checks ranging in side length 107 
 5 
from 400’, 200’,100’, 50’, 25’,12.5’ and 6.25’, presented in a 30 degree stimulus field. Flash VEPs were 108 
produced in response to flash strength 4 from a hand held Grass strobe presented at 30cm from the 109 
patient. OCT was performed using the SPECTRALIS® system (Heidelberg Engineering Ltd. 110 
Hertfordshire, UK). The mean RNFL thickness was calculated across the inferior, superior, nasal and 111 
temporal segments. 112 
 113 
Standard Protocol Approvals, Registrations, and Patient Consents 114 
This study was approved by Great Ormond Street Hospital Research and Development Department 115 
(reference: 16NC10).  116 
 117 
Statistical analysis 118 
Statistical analysis was performed using commercially available software GraphPad Prism 6 (GraphPad 119 
Software Inc) and R 3.3.2. As the AQP4-ON group comprised only four children, MOG-ON and AQP4-120 
ON were combined together as antibody-associated ON (Ab-ON) for statistical analysis. To compare 121 
variables between MS-ON to Ab-ON, non-parametric statistical tests (Mann-Whitney tests) were used 122 
for continuous distributions, and Fisher’s exact tests for nominal data. We explored the association 123 
between RNFL thickness and clinical parameters in all patients together using Spearman’s rank 124 
correlation coefficient. Owing to the limited sample sizes, p-values were used sparingly, using an 125 
arbitrary level of 5% significance (two-tailed). 126 
 127 
Results  128 
Baseline characteristics and clinical features at presentation with ON 129 
A total of 42 children (all under the age of 18 years) with a history of at least one episode of ON were 130 
identified. 22 patients had MS and 20 had Ab-positive ON (AQP4-Ab positive NMOSD = 4, MOG-Ab-131 
associated disease = 16). Demographics and clinical features at onset of ON are summarised in Table 132 
1. 20/42 (48%) children suffered severe visual impairment during the acute episode (logMAR >= 1.0, i.e. 133 
20/200 or worse). The main differences between MS-ON and Ab-ON disease were older age at 134 
presentation in MS-ON (13 years MS-ON vs 8 years Ab-ON, p<0.0001), and more frequent finding of 135 
abnormal MRI brain in MS-ON than Ab-ON (21/22 (95%) MS-ON vs 2/20 (10%) Ab-ON (p<0.0001) 136 
(Table 1).  137 
 138 
Clinical outcomes 139 
Median length of follow up from first clinical presentation was 4 years (IQR 3-7). Clinical parameters at 140 
final follow up are summarised in Table 2a. Recurrence of ON was more common in the Ab-ON group 141 
compared to the MS-ON group (15/20 (75%) Ab-ON vs 7/22 (32%) MS-ON, p=0.0068); in particular, 142 
13/16 (81%) MOG-Ab positive patients had recurrent ON. The total number of ON relapses was also 143 
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higher in Ab-ON children (median 1, range 0-10) compared to MS-ON (median 0, range 0-6) (p=0.029) 144 
(Figure 1a). 145 
 146 
By the end of follow up, 71/84 (85%) eyes had been affected by clinically apparent episodes of optic 147 
neuritis; of these 63/71 (89%) had ophthalmology follow up assessments, at a median interval of 2.1 148 
years (range 0.4-10.3). Median logMAR in eyes with a history of ON at final follow up was 0.02 (IQR 149 
0.00-0.18) (Figure 1b). 12/42 (29%) children had persisting impairment of colour vision, defined as >1 150 
error on Ishihara plate testing. Overall a complete functional recovery of vision occurred in 25/42 (60%) 151 
children; 8/38 (21%) had at least moderately impaired vision (logMAR>0.5) in their worst eye, including 152 
4/38 (11%) who were blind (logMAR>1.3) in their worst eye. Children with AQP4-Ab were more likely to 153 
be blind in at least one eye than AQP4-Ab negative children (2/4 vs 2/34, p=0.043); none of the children 154 
with MOG-Ab were blind. 155 
 156 
Electrophysiological outcomes 157 
Electrodiagnostic tests (EDT), including VEP, were carried out in 24/42 children (57%); three were 158 
excluded as they were carried out during the acute phase of ON, leaving 21/42 children (50%) with EDT 159 
included in the study, performed at median 1.68 years interval after first presentation with ON (range 160 
0.2-8.4). VEP was abnormal in 22/33 (67%) eyes with a clinical history of ON and 2/9 (22%) eyes 161 
without a history of ON. Electrophysiological parameters are summarised in Table 2a. 162 
 163 
Microstructural outcomes 164 
OCT was carried out in 31/42 (74%) children. Assessments were performed outside the acute phase of 165 
ON at a median 1.81 years interval after first presentation with ON (range 0.2-10.3). Retinal 166 
microstructural parameters are summarised in Table 2a. Abnormal RNFL thinning in >=1 segment was 167 
observed in 33/51 (64.7%) eyes with a history of ON and 1/11 (9%) eyes without a history of ON. 168 
Median RNFL thickness in ON eyes (averaged across all four segments) was 76μm (IQR 65.3-84μm) 169 
versus 100.8μm (IQR 89.3-107μm) in non-ON eyes (p=0.0002) (Table  2a). Serial OCT was performed 170 
in 9/31 (29%) cases (5 MOG-Ab, 4 MS) (Table 2b). The mean decline in RNFL (over a median interval 171 
of 1.88 years, range 0.31-3.48) was 2.06μm (±6.02 μm SD) (p=0.17, paired t test). 172 
 173 
The Ab-ON group had a higher rate of optic nerve atrophy as determined by disc pallor compared to the 174 
MS-ON group (17/20 vs 12/22, p=0.047).  175 
 176 
Correlation between RNFL thickness, number of relapses and final visual outcome 177 
Among ON eyes there was an inverse correlation between mean RNFL thickness and visual impairment 178 
(logMAR) (r=-0.41, p=0.0081) (Figure 2b). There was no significant relationship between number of ON 179 
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episodes and mean RNFL (r=-0.18, p=0.3), nor any significant relationship between number of ON 180 
episdes and visual impairment (r=0.03, p=0.8). 181 
 182 
Discussion  183 
In this large cohort of children with RDS and ON, 48% of children had a non-MS phenotype; ON 184 
occurred more frequently in the antibody-mediated group compared to those with MS. Clinical 185 
characteristics at ON presentation such as pain, bilateral involvement and severity of acute visual loss 186 
did not differ between groups, and were similar to a historical cohort from the same three tertiary 187 
centres, comprising children with monophasic, idiopathic ON3. Although lacking statistical significance 188 
due to small numbers of patients with AQP4-Ab NMOSD, it is notable that 75% of AQP4-ON presented 189 
with bilateral involvement (compared to 36% of MS-ON), and 75% of AQP4-ON caused severe visual 190 
loss at nadir (compared to 45% of MS-ON). Interestingly, relapses of ON occurred more frequently in 191 
children with antibody-mediated disease, inkeeping with recent reports in adults in which patients with 192 
MOG-Ab were more likely to have multiple ON relapses17, 26. Nevertheless, complete visual recovery 193 
occurred in 56% of children with MOG-Ab in our cohort, and none were registered blind. HCVA at final 194 
follow up did not differ significantly between groups, although it is notable that children with AQP4-Ab 195 
NMOSD suffered worse visual recovery even after a single episode of ON, with 4 of the 7 worst eyes in 196 
the study belonging to patients with AQP4-Ab NMOSD, and 2/4 (50%) AQP4-ON patients registered 197 
blind at final follow up. We did not identify any significant decline in RNFL over time in those undergoing 198 
serial OCT, suggesting a severe first attack of ON may be the more important determinant of 199 
microstructural damage in RDS than subsequent relapses.    200 
 201 
A key finding in this study was the absence of any correlation between number of relapses and visual 202 
outcome, alongside a significant correlation between RNFL thinning and worse visual outcome. We 203 
detected RNFL thinning on OCT in 56% of MS-ON eyes and 75% of Ab-ON eyes, similar to a recent 204 
study identifying RNFL thinning in 50% of children with MS and a history of ON14. OCT offers an 205 
opportunity to monitor disease activity and progression non-invasively; in adults with MS, RNFL thinning 206 
is a sensitive and specific predictor of clinical disease activity, independent of lesion accumulation on 207 
MRI brain27. However it is not yet part of routine clinical practice across all paediatric centers, and 208 
robust control data in healthy children remains limited, as is standardization of RNFL measurements, 209 
particularly in the acute phase of ON when swelling may complicate some automated RNFL measures. 210 
In this cohort RNFL did not differ significantly between groups, but RNFL thinning was associated with 211 
poorer visual outcome, in keeping with a previous study of paediatric RDS (Yeh et al Multiple Sclerosis 212 
2009; 15: 802-810). In that study, which included children without any clinical episodes of ON, RNFL 213 
thinning was found to differ by number of ON episodes in the group analysis; in the present study, in 214 
which all children had >=1 clinical episode of ON, the lack of correlation observed between relapse rate 215 
and final visual outcome suggests that RNFL thinning (indicating pre-existing ganglion cell fibre loss) 216 
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may be a more sensitive parameter for monitoring disease activity and prompting treatment escalation 217 
than the relapse rate, in children with a clinical history of ON.  218 
 219 
Our finding of clinically-silent disease by EDT – i.e. abnormal VEP in “non-ON” eyes – is consistent with 220 
previous reports13, 14 and provides further support to the recent MAGNIMS recommendation that the 221 
inclusion of optic nerve disease identified clinically, radiologically or electrophysiologically would 222 
increase the sensitivity of dissemination-in-space criteria for MS28. There was a low rate of VEP 223 
normalisation in ON eyes across all groups, even in those with recovered HCVA; the time course of 224 
remyelination after ON has yet to be fully elucidated. Longitudinal analysis may be more informative in 225 
understanding the disease pathobiologies in the different groups.  226 
 227 
A major limitation of our study is its retrospective nature, with inconsistent visual assessments, which 228 
were performed clinically and not as part of a research protocol. Low-contrast VA and symbol digit 229 
modalities were not routinely assessed at follow up and it is possible that some subtle functional 230 
impairment may have been missed29. The paucity of normative paediatric OCT data, especially 231 
longitudinally, should also be acknowledged. Additionally, our study design and the small numbers are 232 
not optimal for evaluation of treatment effect. Using electrodiagnostic tests we detected clinically silent 233 
disease in a proportion of children with MS, but not in antibody mediated ON, highlighting the need for 234 
further prospective studies with standardised longitudinal analysis of microstructural and 235 
electrophysiological parameters to increase our understanding of the disease pathobiologies.  236 
Nevertheless, this study shows that overall clinical relapse of ON does not adversely affect visual 237 
outcome in most children. As OCT correlates with final visual outcome, it may offer clinical utility as a 238 
tool in the assessment of children with ON; as an objective measure of neuroretinal loss in RDS; and as 239 
a surrogate endpoint to evaluate the benefit of neuroprotective agents. 240 
 241 
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 246 
Figure legend  247 
Figure 1:  Clinical outcome of patients with optic neuritis. (A) Total number of ON relapses at final-248 
follow up (median follow-up time 4 years) in Ab-ON and MS-ON cases. (B) High contrast visual acuity at 249 
final follow up in Ab-ON and MS-ON eyes. AQP4-Ab (square), MOG-Ab (circle), MS (triangle).         250 
 251 
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Figure 2: Correlation of retinal nerve fibre layer thickness (RNFL) with clinical parameters.  (A) total 252 
number of clinical relapses (B) Correlation between mean RNFL thickness and visual impairment in ON 253 
eyes.  254 
 255 
 256 
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Table 1: Demographics and clinical features at initial presentation with ON 
 AQP4-Ab 
positive 
NMOSD 
(n=4) 
MOG-Ab 
associated 
disease 
(n=16) 
Ab-ON 
including 
AQP4-Ab 
and MOG-
Ab cases) 
(n=20) 
MS-ON 
(n=22) 
p-value* 
Age at ON onset in 
years; median (IQR) 
8.5 (5.25-
12.25) 
8 (6.75-
9.25) 
8 (6-10.25) 13 (11.75-
14) 
<0.0001 
Sex (F:M, % female) 3:1 (75%) 9:7 (56%) 12:8 (60%) 14:8 (64%) 1.0 
Ethnicity, Caucasian (%) 1/4 (25%) 10/16 
(63%) 
11/20 (55%) 6/22 (27%)  0.1 
History of previous CNS 
demyelinating events (%) 
2/4 (50%) 5/16 (31%) 7/20 (35%) 5/22 (23%) 0.5 
Total number of previous 
CNS demyelinating 
events; median (range) 
0.5 (0-1) 0 (0-2) 0 (0-2) 0 (0-4) 1.0 
Painful ON  1/4 (25%) 9/16  
(56%) 
10/20 (50%) 10/22 
(45%) 
1.0 
Bilateral ON 3/4 (75%) 9/16 (56%) 12/20 (60%) 8/22 (36%) 0.2 
Several visual 
impairment at nadir 
(logMAR >= 1.0)  
3/4 (75%) 7/16  
(44%) 
10/20 (50%) 10/22 
(45%) 
1.0 
Abnormal MRI brain 1/4 (25%) 1/16 (6%) 2/20 (10%) 21/22 
(95%) 
<0.0001 
 
 
Table 2a: Clinical, microstructural and electrophysiological outcomes  
 AQP4-Ab 
positive 
NMOSD 
(n=4) 
MOG-Ab-
associated 
disease (n=16) 
Ab-ON 
(including 
AQP4-Ab 
and MOG-
Ab cases) 
(n=20) 
MS-ON 
(n=22) 
p-value* 
Recurrence of ON (%) 2 (50%) 13 (81%) 15 (75%) 7 (32%) 0.0068 
Total number of ON 
relapses; median (range) 
0.5 (0-4) 1 (0-10)  1 (0-10) 0 (0-6) 0.029 
Disc pallor when? 
Baseline?(%) 
4 (100%) 13 (81%) 17 (85%) 12(55%) 0.047 
Impaired colour vision in 
worst affected eye 
(Ishihara <17/17) (%) 
1 (25%) 3 (19%) 4 (20%) 4 (18%) 1 
High contrast visual acuity 
in worst affected eye, 
logMAR; median (IQR) 
1.1 (0-2.2) 0.1 (0.02-0.11) 0.1 (0-0.21) 0 (0-0.23) 0.3 
Complete functional 
recovery in both eyes (%) 
2 (50%) 9 (56%) 11 (55%) 14 (64%) 0.8 
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At least moderately 
impaired vision 
(logMAR>0.5) in worst eye 
(%) 
2 (50%) 2 (13%) 4 (20%) 4 (18%) 1 
Blind (logMAR>1.3) in 
worst eye (%) 
2 (50%) 0 (0%) 2 (10%) 2 (9%) 1 
ON eyes n=8 n=29 n=37 n=34 n/a 
High contrast visual 
acuity, logMAR; 
median (IQR) 
0.5 (0-1.81) 0.06 (0-0.1) 0.06 (0-0.21) 0.01 (0-0.17) 0.3  
Abnormal RNFL 
thinning (%) 
4/4 (100%) 14/20 (70%) 18/24 (75%) 15/27 (56%) 0.24 
Mean RNFL thickness, 
μm; median (IQR) 
- 73 (54.1-84.2) 73 (54.1-
84.2) 
78 (68.8-
85.6) 
0.3 
Inferior RNFL 
thickness, μm; median 
(IQR) 
- 99 (63-112.2) 99 (63-
112.2) 
99 (85.5-
110.5) 
0.44 
Superior RNFL 
thickness, μm; median 
(IQR) 
- 94.5 (73-
108.3) 
94.5 (73-
108.3) 
100 (91.5-
109.5) 
0.21 
Nasal RNFL thickness, 
μm; median (IQR) 
- 50 (42.3-64.3) 50 (42.3-
64.3) 
56 (50-63) 0.28 
Temporal RNFL 
thickness, μm; median 
(IQR) 
- 45.5 (39-50.8) 45.5 (39-
50.8) 
48 (37.5-60) 0.45 
Abnormal VEP (%) 2/2 (100%) 7/13 (54%) 9/15 (60%) 13/18 (72%) 0.7 
Non-ON eyes n=0 n=3 n=3 n=10 n/a 
High contrast visual 
acuity, logMAR; 
median (IQR) 
- 0 (0-0.01) 0 (0-0.01) 0 (0-0) n/a 
Abnormal RNFL 
thinning (%) 
- 0/2 (0%) 0/2 (0%) 1/9 (11%) 1 
Mean RNFL thickness, 
μm; median (IQR) 
- 110.9 (110.8-
110.9) 
110.9 
(110.8-
110.9) 
95.5 (87.4-
100.9) 
n/a 
Inferior RNFL 
thickness, μm; median 
(IQR) 
- 153 (145-161) 153 (145-
161) 
119 (107-
127.5) 
n/a 
Superior RNFL 
thickness, μm; median 
(IQR) 
- 133.5 (125.3-
141.8) 
133.5 
(125.3-
141.8) 
127 (115-
132) 
n/a 
Nasal RNFL thickness, 
μm; median (IQR) 
- 84.5 (83.8-
85.2) 
84.5 (83.8-
85.2) 
75 (63-77) n/a 
Temporal RNFL 
thickness, μm; median 
(IQR) 
- 72.5 (71.8-
73.3) 
72.5 (71.8-
73.3) 
67 (60.5-68) n/a 
Abnormal VEP (%) - 1/3 (33%) 1/3 (33%) 1/6 (17%) 1 
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Table 2b: Serial optical coherence tomography 
 
 MOG-Ab-
associated 
disease (n=5) 
MS-ON 
(n=4) 
 
p-value* 
ON eyes n=9 n=6 n/a 
Abnormal RNFL 
thinning (%) 
9/9 (100%) 4/6 (67%) 0.15 
Mean RNFL thickness, 
μm; median (IQR) 
65.3 (47.5-
70.8) 
76.8 (59.6-
83.4) 
0.14 
Change in mean RNFL 
thickness from 
baseline, μm; mean 
(±SD) 
-4.4 (±6.9) -0.83 (±3)  
Non-ON eyes n=1 n=2 n/a 
Abnormal RNFL 
thinning (%) 
0/1 (0%) 1/2 (50%) n/a 
Mean RNFL thickness, 
μm; median (IQR) 
119.3 90.3 (88.5-
92) 
n/a 
Change in mean RNFL 
thickness from 
baseline, μm; mean 
(±SD) 
8.5 -0.3 (±2.1) n/a 
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